Saphris (Asenapine) is a drug that was approved by the FDA in 2007 for the treatment of schizophrenia and the manic phases of bipolar disorder. It functions by acting primarily on 5-HT2A serotonergic receptors and D2 dopaminergic receptors as an antagonist. It also elicits effects on a variety of other serotonergic receptors (5HT2B, 5HT2C, 5HT6, […]
↧